Melanoma is a fatal skin malignant tumor with a poor prognosis. We found that long noncoding RNA BASP1‐AS1 is essential for the development and prognosis of melanoma. The methylation, RNA sequencing, copy number variation, mutation data, and sample follow‐up information of melanoma from The Cancer Genome Atlas (TCGA) were analyzed using weighted gene co‐expression network analysis and 366 samples common to the three omics were selected for multigroup clustering analysis. A four‐gene prognostic model (BASP1‐AS1, LOC100506098, ARHGAP27P1, and LINC01532) was constructed in the TCGA cohort and validated using the GSE65904 series. The expression of BASP1‐AS1 was upregulated in melanoma tissues and various melanoma cell lines. Functionally, the ectopic expression of BASP1‐AS1 promoted cell proliferation, migration, and invasion in both A375 and SK‐MEL‐2 cells. Mechanically, BASP1‐AS1 interacted with YBX1 and recruited it to the promoter of NOTCH3, initiating its transcription process. The activation of the Notch signaling then resulted in the transcription of multiple oncogenes, including c‐MYC, PCNA, and CDK4, which contributed to melanoma progression. Thus, BASP1‐AS1 could act as a potential biomarker for cutaneous malignant melanoma. We identified a new type of long noncoding RNA (LncRNA) BASP1‐AS1, which can promote melanoma development both in vivo and in vitro. Detailed studies on the molecular mechanism showed that BASP1‐AS1 promoted the proliferation, invasion, and migration of melanoma cells by regulating YBX1. In addition, LncRNA BASP1‐AS1 is a poor prognostic indicator and a potential therapeutic target for melanoma.